Form 4: Inari Medical Director William Hoffman Sells Shares Under 10b5-1 Plan

Director William Hoffman of Inari Medical sold a total of 60,000 shares of common stock on November 18, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• William Hoffman, a director at Inari Medical, sold 60,000 shares of the company's common stock on November 18, 2024.
• The sales were executed in multiple transactions at varying prices, ranging from $49.65 to $52.59 per share.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Mr. Hoffman's direct ownership of Inari Medical stock decreased to 501,233 shares.

Sentiment

Score: 5

Explanation: The document is neutral as it reports a routine insider stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Negatives

• The sale of 60,000 shares by a director could be perceived negatively by some investors.

Risks

• Sales by insiders, even under a 10b5-1 plan, can sometimes be interpreted as a lack of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.
• The volume of shares sold is not unusual for a director of a company of Inari Medical's size.
• Comparable companies would also have similar filings when directors sell shares.

Stakeholder Impact

• The stock sale may have a minor negative impact on shareholder sentiment.

Key Dates

Keywords

Inari Medical, William Hoffman, insider trading, stock sale, Form 4, 10b5-1 plan, NARI